The designer antiangiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models

• Published in: The FASEB journal 2002-12, Vol.16 (14), p.1991-1993
• Main Authors: Schaft, Daisy W. J., Dings, Ruud P. M., Lussanet, Quido G., Eijk, Loes I., Nap, Annemiek W., Beets‐Tan, Regina G.H., Bouma‐Ter Steege, Jessica C. A., Wagstaff, John, Mayo, Kevin H., Griffioen, Arjan W.
• Format: Article
• Language: English
• Subjects: apoptosis; melanoma; migration; ovarian carcinoma
• ISSN: 0892-6638; 1530-6860
• DOI: 10.1096/fj.02-0509fje

ABSTRACT The de novo designed angiogenesis inhibitor anginex was tested in vitro and in vivo for its mechanism of action and antitumor activity. The data presented here demonstrate that anginex is a powerful antiangiogenic agent with significant antitumor activity. The mechanism of action of anginex was found to be the induction of anoikis leading to apoptosis in angiogenically activated endothelial cells, resulting in an up to 90% inhibition of migration in the wound assay. Anginex inhibited angiogenesis as demonstrated in the in vitro mouse aortic ring assay. In addition, tumor‐induced angiogenesis in the chick chorioallantoic membrane was markedly inhibited. Anginex showed profound antitumor activity in the syngeneic mouse B16F10 melanoma model and in a xenograft human tumor model. Microvessel density determination as well as magnetic resonance imaging showed that the antitumor activity in these tumor models resulted from the antiangiogenic activity of anginex. A complete absence of toxicity was observed in these models. The data presented here demonstrate that anginex is a promising agent for further clinical development.